Cortexyme Financial Statements ()
|
|
|
|
Report date
|
|
|
06.08.2021 |
29.10.2021 |
01.03.2022 |
10.05.2022 |
09.08.2022 |
|
09.08.2022 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
Operating Income, bln rub |
|
|
-21.8 |
-21.7 |
-89.9 |
-21.6 |
-16.3 |
|
-149.4 |
|
EBITDA, bln rub |
? |
|
-21.8 |
-21.6 |
-23.8 |
-21.9 |
-16.3 |
|
-83.5 |
|
Net profit, bln rub |
? |
|
-21.8 |
-21.7 |
-89.9 |
-21.7 |
-16.6 |
|
-149.9 |
|
|
OCF, bln rub |
? |
|
-17.6 |
-17.3 |
-14.4 |
-16.1 |
|
|
-47.9 |
|
CAPEX, bln rub |
? |
|
0.099 |
0.000 |
0.044 |
0.005 |
|
|
0.049 |
|
FCF, bln rub |
? |
|
-17.7 |
-17.3 |
-14.5 |
-16.1 |
|
|
-47.9 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
|
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
|
OPEX, bln rub |
|
|
21.8 |
21.7 |
90.3 |
21.9 |
16.3 |
|
150.1 |
|
Cost of production, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
R&D, bln rub |
|
|
14.7 |
14.0 |
60.8 |
12.8 |
7.20 |
|
94.8 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.072 |
0.590 |
|
0.662 |
|
|
Assets, bln rub |
|
|
161.4 |
147.4 |
133.2 |
116.1 |
117.9 |
|
117.9 |
|
Net Assets, bln rub |
? |
|
142.1 |
132.7 |
118.6 |
106.4 |
111.5 |
|
111.5 |
|
Debt, bln rub |
|
|
0.773 |
0.610 |
0.420 |
0.339 |
0.133 |
|
0.133 |
|
Cash, bln rub |
|
|
130.0 |
114.4 |
106.8 |
91.5 |
94.7 |
|
94.7 |
|
Net debt, bln rub |
|
|
-129.2 |
-113.8 |
-106.4 |
-91.2 |
-94.5 |
|
-94.5 |
|
|
Ordinary share price, rub |
|
|
53.0 |
91.7 |
12.6 |
6.19 |
2.22 |
|
2.22 |
|
Number of ordinary shares, mln |
|
|
29.6 |
29.8 |
29.8 |
30.1 |
32 467 |
|
32 467 |
|
|
Market cap, bln rub |
|
|
1 568 |
2 728 |
376 |
187 |
72 077 |
|
72 077 |
|
EV, bln rub |
? |
|
1 439 |
2 615 |
269 |
95 |
71 982 |
|
71 982 |
|
Book value, bln rub |
|
|
142 |
133 |
119 |
106 |
105 |
|
105 |
|
|
EPS, rub |
? |
|
-0.74 |
-0.73 |
-3.02 |
-0.72 |
0.00 |
|
0.00 |
|
FCF/share, rub |
|
|
-0.60 |
-0.58 |
-0.49 |
-0.53 |
0.00 |
|
0.00 |
|
BV/share, rub |
|
|
4.80 |
4.46 |
3.98 |
3.53 |
0.00 |
|
0.00 |
|
|
FCF yield, % |
? |
|
-3.63% |
-2.27% |
-16.8% |
-35.1% |
-0.07% |
|
-0.07% |
|
ROE, % |
? |
|
-61.2% |
-65.7% |
-132.0% |
-145.8% |
-134.4% |
|
-134.4% |
|
ROA, % |
? |
|
-53.8% |
-59.1% |
-117.5% |
-133.6% |
-127.2% |
|
-127.2% |
|
|
P/E |
? |
|
-18.0 |
-31.3 |
-2.40 |
-1.20 |
-480.7 |
|
-480.7 |
|
P/FCF |
|
|
-27.5 |
-44.1 |
-5.95 |
-2.85 |
-1 505 |
|
-1 505 |
|
P/BV |
? |
|
11.0 |
20.6 |
3.17 |
1.75 |
687.7 |
|
687.7 |
|
EV/EBITDA |
? |
|
-16.9 |
-30.7 |
-2.99 |
-1.07 |
-861.6 |
|
-861.6 |
|
Debt/EBITDA |
|
|
1.51 |
1.34 |
1.18 |
1.02 |
1.13 |
|
1.13 |
|
|
R&D/CAPEX, % |
|
|
14 868% |
|
138 170% |
255 140% |
|
|
193 447% |
|
| Cortexyme shareholders |
